AU2012356890B2 - Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors - Google Patents

Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors Download PDF

Info

Publication number
AU2012356890B2
AU2012356890B2 AU2012356890A AU2012356890A AU2012356890B2 AU 2012356890 B2 AU2012356890 B2 AU 2012356890B2 AU 2012356890 A AU2012356890 A AU 2012356890A AU 2012356890 A AU2012356890 A AU 2012356890A AU 2012356890 B2 AU2012356890 B2 AU 2012356890B2
Authority
AU
Australia
Prior art keywords
ethyl
boronic acid
hplc
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012356890A
Other languages
English (en)
Other versions
AU2012356890A1 (en
Inventor
Stefano Crosignani
Federica MORANDI
Jeyaprakashnarayanan SEENISAMY
Dominique Swinnen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Publication of AU2012356890A1 publication Critical patent/AU2012356890A1/en
Application granted granted Critical
Publication of AU2012356890B2 publication Critical patent/AU2012356890B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2012356890A 2011-12-22 2012-12-21 Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors Ceased AU2012356890B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161579076P 2011-12-22 2011-12-22
EP11195107 2011-12-22
EP11195107.5 2011-12-22
US61/579,076 2011-12-22
PCT/EP2012/076595 WO2013092979A1 (en) 2011-12-22 2012-12-21 Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors

Publications (2)

Publication Number Publication Date
AU2012356890A1 AU2012356890A1 (en) 2014-08-07
AU2012356890B2 true AU2012356890B2 (en) 2017-06-08

Family

ID=48667763

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012356890A Ceased AU2012356890B2 (en) 2011-12-22 2012-12-21 Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors

Country Status (15)

Country Link
US (1) US9688702B2 (https=)
EP (1) EP2793900B1 (https=)
JP (1) JP6129203B2 (https=)
KR (1) KR20140114391A (https=)
CN (1) CN104321060B (https=)
AU (1) AU2012356890B2 (https=)
BR (1) BR112014015363A8 (https=)
CA (1) CA2860142C (https=)
EA (1) EA201400735A1 (https=)
ES (1) ES2699267T3 (https=)
HK (1) HK1206261A1 (https=)
IL (1) IL233200A (https=)
MX (1) MX352652B (https=)
SG (2) SG11201403254QA (https=)
WO (1) WO2013092979A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US9464098B2 (en) 2012-12-03 2016-10-11 Hoffmann-La Roche Inc. Substituted triazole boronic acid compounds
AU2013355110B2 (en) 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2015008627A (es) * 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
ES2748434T3 (es) 2014-01-10 2020-03-16 Univ Cornell Dipéptidos como inhibidores de inmunoproteasomas humanos
ES2750805T3 (es) 2014-05-05 2020-03-27 Rempex Pharmaceuticals Inc Síntesis de sales de boronato y usos de las mismas
EP3139930B1 (en) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2016003929A1 (en) * 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3193904B1 (en) 2014-08-18 2025-10-01 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
JP6662865B2 (ja) * 2014-10-01 2020-03-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ボロン酸誘導体
RU2017115193A (ru) * 2014-10-01 2018-11-06 Мерк Патент Гмбх Производные бороновой кислоты
BR112017006420A2 (pt) 2014-10-01 2017-12-19 Merck Patent Gmbh derivados de ácido borônico
RU2017115191A (ru) * 2014-10-01 2018-11-06 Мерк Патент Гмбх Производные бороновой кислоты
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR102764027B1 (ko) 2015-10-15 2025-02-07 코넬 유니버시티 프로테아좀 억제제 및 이의 용도
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途
MX389349B (es) 2016-06-30 2025-03-20 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos.
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
PL3672977T3 (pl) 2017-08-24 2022-09-26 Merck Patent Gmbh Pochodne kwasu boronowego
US11286270B2 (en) 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
EP3694605A4 (en) 2017-10-11 2021-10-27 Cornell University PEPTIDOMIMETIC PROTEASOME INHIBITORS
CN107556336A (zh) * 2017-10-16 2018-01-09 康化（上海）新药研发有限公司 一种呋喃‑2‑甲烷基硼酸频哪醇酯的合成方法
MA50906A (fr) 2017-11-16 2020-09-23 Principia Biopharma Inc Inhibiteurs d'immunoprotéasome
ES2928787T3 (es) 2017-11-16 2022-11-22 Principia Biopharma Inc Inhibidores del inmunoproteasoma
CN108130370B (zh) * 2018-01-05 2020-11-17 武汉惠康达科技有限公司 Psmb8及其抑制剂在制备治疗脂肪肝及其相关疾病药物中的应用
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
SG11202100727VA (en) 2018-07-26 2021-02-25 Merck Patent Gmbh Boronic acid derivatives
BR112021010095A2 (pt) 2018-11-29 2021-09-28 VenatoRx Pharmaceuticals, Inc. Composições de combinação que compreendem um inibidor de beta-lactamase e usos das mesmas
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
CN114075227B (zh) * 2020-08-19 2023-07-04 北京嵩润医药科技有限责任公司 吡唑硼酸类化合物、包含其的药物组合物及它们的用途
US20250340577A1 (en) * 2021-03-02 2025-11-06 Case Western Reserve University Beta-lactomase inhibitors and uses thereof
CN116940580A (zh) * 2021-03-05 2023-10-24 Ａｇｃ株式会社 化合物、化合物的制造方法及表面处理剂的制造方法
WO2023006863A1 (en) 2021-07-29 2023-02-02 Merck Patent Gmbh Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain
CN118119630A (zh) * 2021-10-14 2024-05-31 首药控股(北京)股份有限公司 硼酸衍生物
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts
WO2025111328A1 (en) 2023-11-21 2025-05-30 VenatoRx Pharmaceuticals, Inc. Citrate coordination complex of an orally-delivered beta-lactamase inhibitor and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051581A1 (en) * 2007-10-16 2009-04-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
WO2009064413A1 (en) * 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2010036357A1 (en) * 2008-09-29 2010-04-01 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
WO2011123502A1 (en) * 2010-03-31 2011-10-06 Millennium Pharmaceuticals, Inc Derivatives of 1-amino-2-cyclopropylethylboronic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
US7332343B2 (en) 2004-01-16 2008-02-19 Board Of Regents, The University Of Texas System Determining enantiomeric excess using indicator-displacement assays
HRP20212002T1 (hr) * 2004-03-30 2022-04-01 Millennium Pharmaceuticals, Inc. Sinteza estera i spojeva borove kiseline
CA2668662A1 (en) 2006-11-14 2008-05-22 Merck & Co., Inc. Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AU2007357338B2 (en) * 2007-08-06 2014-03-20 Takeda Pharmaceutical Company Limited Proteasome inhibitors
US8507494B2 (en) 2010-04-30 2013-08-13 Merck Sharp & Dohme Corp. Heterocyclic quinolizine derived M1 receptor positive allosteric modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009051581A1 (en) * 2007-10-16 2009-04-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
WO2009064413A1 (en) * 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2010036357A1 (en) * 2008-09-29 2010-04-01 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
WO2011123502A1 (en) * 2010-03-31 2011-10-06 Millennium Pharmaceuticals, Inc Derivatives of 1-amino-2-cyclopropylethylboronic acid

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ELLIOTT P J ET AL: "Proteasome inhibition: a new anti-inflammatory strategy", JOURNAL OF MOLECULAR MEDICINE (2003), Vol. 81, no. 4, pages 235-245 *
JIN S ET AL: "Identification of the first fluorescent alpha-amidoboronic acids that change fluorescent properties upon sugar binding", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009), vol. 19, no. 6, pages 1596-1599 *
MATTESON D S ET AL: "Cesium alkyltrifluoroborates from asymmetric boronic esters", SYNLETT, no. 20, 2006, pages 3501-3503, , ISSN: 0936-5214, DOI: 10.1055/s-2006-956476 *
MATTESON D S ET AL: "Hydrolysis of Substituted 1,3,2-Dioxaborolanes and an Asymmetric Synthesis of a Differentially Protected syn , syn -3-Methyl-2,4-hexanediol", JOURNAL OF ORGANIC CHEMISTRY (1996), vol. 61, no. 17, pages 6047-6051 *
MATTESON D S ET AL: "Synthesis of 1-amino-2-phenylethane-1-boronic acid derivatives", ORGANOMETALLICS, vol. 3, no. 4, April 1984 (1984-04), pages 614-618, , ISSN: 0276-7333, DOI: 10.1021/om00082a019 *
Matteson et al. "R-1-Acetamido-2-phenylethaneboronic acid. A specific transition-state analog for chymotrypsin" Journal of the American Chemical Society, 1981, Vol 103, Pages 5241-5242. *
Morandi et al. "Nanomolar Inhibitors of AmpC ß-Lactamase" Journal of the American Chemical Society, 2003, Vol 125, Pages 685-695. *

Also Published As

Publication number Publication date
SG11201403254QA (en) 2014-07-30
CN104321060A (zh) 2015-01-28
EP2793900B1 (en) 2018-08-22
AU2012356890A1 (en) 2014-08-07
MX2014007362A (es) 2014-08-01
CA2860142C (en) 2020-10-27
JP6129203B2 (ja) 2017-05-17
US20140364396A1 (en) 2014-12-11
MX352652B (es) 2017-12-04
IL233200A (en) 2017-08-31
WO2013092979A1 (en) 2013-06-27
SG10201605152SA (en) 2016-08-30
US9688702B2 (en) 2017-06-27
IL233200A0 (en) 2014-07-31
CN104321060B (zh) 2018-08-07
EA201400735A1 (ru) 2015-04-30
BR112014015363A2 (pt) 2017-06-13
JP2015502387A (ja) 2015-01-22
BR112014015363A8 (pt) 2017-06-13
KR20140114391A (ko) 2014-09-26
ES2699267T3 (es) 2019-02-08
EP2793900A1 (en) 2014-10-29
HK1206261A1 (en) 2016-01-08
CA2860142A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
AU2012356890B2 (en) Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
US10640520B2 (en) Boronic acid derivatives
US10253049B2 (en) Boronic acid derivatives
US10669289B2 (en) Boronic acid derivatives
EP3201207B1 (en) Boronic acid derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired